NPPB and hydrops fetalis: The DELIVER trial (NCT03619213) investigates the effects of dapagliflozin in patients with HFpEF (EF >40%, structural heart disease, elevated NT-pro BNP levels, NYHA II–IV) on cardiovascular death or HF events.